Aktienanalyse wird geladen …
LLY · NYSE · Pharmaceuticals · USA
1.183,09 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 65,18 Mrd. | 20,64 Mrd. | 22,95 $ | 899,3 Mio. | 0,5 Mio · 0,1 % | 5,3 Mio · 0,6 % | 83 % | 31,7 % | 6,63 $ | 0,70 $ | 6,00 $ |
| 2024 | 45,04 Mrd. | 10,59 Mrd. | 11,71 $ | 904,1 Mio. | 0,5 Mio · 0,1 % | — | 81,3 % | 23,5 % | 0,46 $ | 0,71 $ | 5,20 $ |
| 2023 | 34,12 Mrd. | 5,24 Mrd. | 5,80 $ | 903,3 Mio. | 0,5 Mio · 0,1 % | 1,9 Mio · 0,2 % | 79,3 % | 15,4 % | -3,49 $ | 0,70 $ | 4,52 $ |
| 2022 | 28,54 Mrd. | 6,24 Mrd. | 6,90 $ | 904,62 Mio. | 0,3 Mio · 0 % | 7,4 Mio · 0,8 % | 76,8 % | 21,9 % | 5,09 $ | 0,41 $ | 3,92 $ |
| 2021 | 28,32 Mrd. | 5,58 Mrd. | 6,12 $ | 911,68 Mio. | 0,3 Mio · 0 % | 1,1 Mio · 0,1 % | 74,2 % | 19,7 % | 5,91 $ | 0,38 $ | 3,40 $ |
| 2020 | 24,54 Mrd. | 6,19 Mrd. | 6,79 $ | 912,51 Mio. | 0,3 Mio · 0 % | 23,4 Mio · 2,6 % | 77,7 % | 25,2 % | 4,90 $ | 0,34 $ | 2,96 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge |
|---|---|---|---|---|---|
| Q2 2026 | 22,97 Mrd. | 7,1 Mrd. | 7,94 $ | 893,7 Mio. | 30,9 % |
| Q1 2026 | 19,8 Mrd. | 7,4 Mrd. | 8,26 $ | 895,9 Mio. | 37,4 % |
| Q4 2025 | 19,29 Mrd. | 6,64 Mrd. | 7,38 $ | 898 Mio. | 34,4 % |
| Q3 2025 | 17,6 Mrd. | 5,58 Mrd. | 6,21 $ | 898,8 Mio. | 31,7 % |
| Q2 2025 | 15,56 Mrd. | 5,66 Mrd. | 6,29 $ | 899,8 Mio. | 36,4 % |
| Q1 2025 | 12,73 Mrd. | 2,76 Mrd. | 3,06 $ | 900,6 Mio. | 21,7 % |
| Q4 2024 | 13,53 Mrd. | 4,41 Mrd. | 4,90 $ | — | 32,6 % |
| Q3 2024 | 11,44 Mrd. | 970,3 Mio. | 1,07 $ | 905 Mio. | 8,5 % |
Eli Lilly (LLY) Stock Is Up, What You Need To Know
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
Eli Lilly breaks ground on $6.5B Houston manufacturing plant
Medicare just handed Eli Lilly a massive weight-loss win
Lilly Jumps 3.64% While a $100 Billion Obesity Race Crowds In
Can Eli Lilly Stock Catch Up To Rivals It Outgrows?
Eli Lilly and InnoCare sign drug discovery deal worth up to $3.35B
Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare
Eli Lilly and Company is a global medicine company focused on discovering, developing, manufacturing, and marketing human pharmaceutical products. Eli Lilly and Company operates across major therapeutic areas including diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular care, serving patients, healthcare providers, and health systems worldwide. Its current portfolio includes widely used treatments for chronic metabolic conditions as well as therapies for cancer and immune-related diseases, supported by ongoing commercial operations and regulated manufacturing capacity in the United States, Europe, and Asia. The company also advances diagnostics and specialty medicines that address complex medical needs in hospital, outpatient, and community settings. Eli Lilly and Company plays a significant role in the pharmaceutical market through its broad product lineup, large-scale distribution network, and focus on prescription medicines that are used in everyday clinical practice.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest LLY und jede andere Aktie unbegrenzt.